Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Dennis Thompson HealthDay Reporter ... confirmed case of Ebola has surfaced in the United States, ... health officials announced late Tuesday. The critically ill patient, ... has been diagnosed with the deadly virus, officials from ... a late afternoon news conference. The man is receiving ...
(Date:9/30/2014)... Alan Mozes Health ... News) -- Colon cancer patients who are overweight or ... risk for developing a second weight-related cancer, new research ... risk of colon cancer recurrence, only the potential for ... found that colorectal cancer survivors who reported being overweight ...
(Date:9/30/2014)... slow the spiraling costs of drugs paid for by ... no meaningful impact on cancer chemotherapy drug costs, say ... Clinical Oncology published online today. , "We looked ... lung cancers, and did not find a substantial change ... of the recent Medicare law in 2005," says the ...
(Date:9/30/2014)... by UC Irvine immunologists reveals new information about how ... process that determines how the body,s ability to fight ... Nature Immunology , neurology professor Dr. Michael Demetriou, postdoctoral ... describe a critical mechanism underlying how T cells are ... T cell is a type of blood cell called ...
(Date:9/30/2014)... Fat Burning Kitchen , the latest diet guide ... that is helping people learn the truth about so-called health ... in less than 24 hours has caught the attention of ... culture that is becoming so obsessed with diets and weight ... fact and fiction when it comes to health foods, eating ...
Breaking Medicine News(10 mins):Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3
... HealthDay Reporter , THURSDAY, Dec. 8 (HealthDay News) -- ... of oral contraceptives carry revised labels warning about an ... The U.S. Food and Drug Administration advisers voted 21-5 ... such as Bayer,s Yaz or Yasmin. Both contain a ...
... (HealthDay News) -- Flu vaccination is easy to get and ... the flu season, but too few Americans take advantage of ... the flu, yet every year it strikes up to 20 ... and killing thousands," Dr. Thomas Slama, president of the Infectious ...
... Pig stem cell research conducted by two animal scientists ... to determine the safety of future stem cell therapies ... inadequate for testing many human therapiesincluding pharmaceuticalssince 50 percent ... regardless of their source or identity, according to Thomas ...
... -- Children born to mothers with postpartum depression are at ... oxytocin may reduce the risk, according to a new study. ... has been associated with feelings of love and trust, may ... the researchers found. A synthetic version of the hormone is ...
... the Centre for Reviews and Dissemination (CRD) at the ... PubMed Health is a new online service provided by ... US National Library of Medicine (NLM) the world,s ... text of selected systematic reviews and also provides information ...
... on the geographic mobility of registered nurses (RNs) recently published ... the profession,s relative lack of mobility has serious implications for ... According to the studypart of the RN Work Project funded ... of newly licensed RNs work within 40 miles of where ...
Cached Medicine News:Health News:FDA Advisers: Newer Forms of the 'Pill' Need Revised Warning Labels 2Health News:FDA Advisers: Newer Forms of the 'Pill' Need Revised Warning Labels 3Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Pig-induced pluripotent stem cells may be safer than previously thought 2Health News:'Love Hormone' May Buffer Kids From Mom's Depression 2Health News:New registered nurses' lack of geographic mobility has negative implications for rural health 2Health News:New registered nurses' lack of geographic mobility has negative implications for rural health 3
(Date:9/30/2014)... , Sept. 30, 2014 This report analyzes ... by the following Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, ... for the US Canada, Japan , ... Latin America , and Rest of World. Annual ... 2018. Also, a six-year historic analysis is provided for these ...
(Date:9/30/2014)... Sept. 30, 2014  Tasly Pharmaceuticals, Inc., the ... medicine, announced today the launch of Deepure. ... to address men and women concerned with supporting ... into old age while helping keep their health ... whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
Breaking Medicine Technology:Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... National Stem,Cell Holding, Inc. (OTC: NHGI.PK), today ... Jacob Cohen, have discovered biomaterial derived from,non- embryonic ... in,various wound care applications. On July 26, ... embryonic stem cell lines, Michael and Jacob Cohen ...
... Aug. 14 StatSure,Diagnostic Systems, Inc. (OTC Bulletin Board: ... "barrel- test" format for the detection of,antibodies to HIV-1/2 ... trials needed for a CLIA waiver application and that ... & Drug Administration (FDA) for,their review. The Company believes ...
Cached Medicine Technology:National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 3CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 2CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 3
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... Katena Products, Inc. is ... company dedicated exclusively to ophthalmic ... products to over 7,000 customers ... through a global network of ...
... food, exercise, stress . . . Theyre ... overall health. Unfortunately, its difficult, and often ... on a daily basis. Its even more ... submit the information to a care provider ...
... Managing diabetes requires making decisions about insulin ... exercise. These decisions are guided by data ... information, and by the patterns that can ... Care Providers when the data is presented ...
Medicine Products: